Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report

Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report

Abstract Background Infliximab (IFX), a mouse-human chimeric monoclonal antibody against human tumor necrosis factor alpha, is used in refractory cases of Takayasu arteritis. Several factors influence the pharmacokinetics of therapeutic antibodies including IFX. Monitoring plasma levels of IFX could...

Full description

Bibliographic Details
Main Authors: Sho Masui, Atsushi Yonezawa, Kazushi Izawa, Makoto Hayakari, Kayoko Asakura, Risa Taniguchi, Masahiko Isa, Hirofumi Shibata, Takahiro Yasumi, Ryuta Nishikomori, Junko Takita, Kazuo Matsubara
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Infliximab
Pharmacokinetics
Takayasu arteritis
LC-MS/MS
Online Access:http://link.springer.com/article/10.1186/s40780-019-0136-4

Internet

http://link.springer.com/article/10.1186/s40780-019-0136-4

Similar Items